Read by QxMD icon Read

Cardiovascular Diabetology

Hanan Amadid, Nanna B Johansen, Anne-Louise Bjerregaard, Søren Brage, Kristine Færch, Torsten Lauritzen, Daniel R Witte, Annelli Sandbæk, Marit E Jørgensen, Dorte Vistisen
BACKGROUND: Ambiguity exists in relation to the role of physical activity (PA) for cardiovascular disease (CVD) risk reduction. We examined the interplay between PA dimensions and more conventional CVD risk factors to assess which PA dimensions were associated with the first CVD event and whether subgroup differences exist. METHODS: A total of 1449 individuals [median age 65.8 (IQR: 61.2, 70.7) years] with low to high risk of type 2 diabetes and free from CVD from the Danish ADDITION-PRO study were included for survival analysis...
September 12, 2018: Cardiovascular Diabetology
Simon Timpka, Amanda Markovitz, Tommy Schyman, Ingrid Mogren, Abigail Fraser, Paul W Franks, Janet W Rich-Edwards
BACKGROUND: Women with history of hypertensive disorders of pregnancy (HDP) are at increased risk of early onset cardiovascular disease and type 2 diabetes (T2D). We aimed to investigate the extent to which HDP is also associated with midlife development of T2D and hypertension above and beyond established risk factors. METHODS: We included parous women who attended population-based structured clinical visits at age 50 and 60 years in Sweden 1991-2013 (N = 6587)...
September 10, 2018: Cardiovascular Diabetology
Kathrin Weidner, Michael Behnes, Tobias Schupp, Jonas Rusnak, Linda Reiser, Armin Bollow, Gabriel Taton, Thomas Reichelt, Dominik Ellguth, Niko Engelke, Jorge Hoppner, Ibrahim El-Battrawy, Kambis Mashayekhi, Christel Weiß, Martin Borggrefe, Ibrahim Akin
OBJECTIVES: The study sought to assess the prognostic impact of type 2 diabetes in patients presenting with ventricular tachyarrhythmias on admission. BACKGROUND: Data regarding the prognostic outcome of diabetics presenting with ventricular tachyarrhythmias is limited. METHODS: A large retrospective registry was used including all consecutive patients presenting with ventricular tachycardia (VT) and fibrillation (VF) on admission from 2002 to 2016...
September 10, 2018: Cardiovascular Diabetology
Beibei Dai, Huaping Li, Jiahui Fan, Yanru Zhao, Zhongwei Yin, Xiang Nie, Dao Wen Wang, Chen Chen
BACKGROUND: Diabetes is a leading cause of mortality and morbidity across the world. Over 50% of deaths among diabetic patients are caused by cardiovascular diseases. Cardiac diastolic dysfunction is one of the key early signs of diabetic cardiomyopathy, which often occurs before systolic dysfunction. However, no drug is currently licensed for its treatment. METHODS: Type 9 adeno-associated virus combined with cardiac Troponin T promoter were employed to manipulate miR-21 expression in the leptin receptor-deficient (db/db) mice...
September 4, 2018: Cardiovascular Diabetology
Raminderjit Kaur, Manpreet Kaur, Jatinder Singh
The incidence and prevalence of diabetes mellitus is rapidly increasing worldwide at an alarming rate. Type 2 diabetes mellitus (T2DM) is the most prevalent form of diabetes, accounting for approximately 90-95% of the total diabetes cases worldwide. Besides affecting the ability of body to use glucose, it is associated with micro-vascular and macro-vascular complications. Augmented atherosclerosis is documented to be the key factor leading to vascular complications in T2DM patients. The metabolic milieu of T2DM, including insulin resistance, hyperglycemia and release of excess free fatty acids, along with other metabolic abnormalities affects vascular wall by a series of events including endothelial dysfunction, platelet hyperactivity, oxidative stress and low-grade inflammation...
August 31, 2018: Cardiovascular Diabetology
Valeska Ormazabal, Soumyalekshmi Nair, Omar Elfeky, Claudio Aguayo, Carlos Salomon, Felipe A Zuñiga
For many years, cardiovascular disease (CVD) has been the leading cause of death around the world. Often associated with CVD are comorbidities such as obesity, abnormal lipid profiles and insulin resistance. Insulin is a key hormone that functions as a regulator of cellular metabolism in many tissues in the human body. Insulin resistance is defined as a decrease in tissue response to insulin stimulation thus insulin resistance is characterized by defects in uptake and oxidation of glucose, a decrease in glycogen synthesis, and, to a lesser extent, the ability to suppress lipid oxidation...
August 31, 2018: Cardiovascular Diabetology
Annette Masuch, Maik Pietzner, Martin Bahls, Kathrin Budde, Gabi Kastenmüller, Stephanie Zylla, Anna Artati, Jerzy Adamski, Henry Völzke, Marcus Dörr, Stephan B Felix, Matthias Nauck, Nele Friedrich
BACKGROUND: The N-terminal prohormone of brain natriuretic peptide (NT-proBNP) is an important biomarker for the diagnosis of heart failure. Apart from this and only recently recognized, NT-proBNP levels associate with higher HDL- and lower LDL-cholesterol levels comprising a favorable blood lipid profile. To further examine this observation, the lipoprotein profile in relation to NT-proBNP was examined in-depth by proton nuclear magnetic resonance spectroscopy (1 H-NMR). We complemented this investigation with a state-of-the-art untargeted metabolomics approach...
August 28, 2018: Cardiovascular Diabetology
Alexander Tenenbaum, Enrique Z Fisman
There is a vast disagreement in relation to the possible beneficial effects of omega-3 polyunsaturated fatty acids (omega-3 PUFA) supplementation in patients with diabetes and cardiovascular disease. The conflicting results between the various original studies and meta-analyses could be partially explained as a result of variable supplementation dosage and duration, either of which may modify the effects of omega-3 PUFA on cardio-metabolic biomarkers. Meta-analyses are limited usually by the inability to draw inferences regarding dosage, duration and the interaction of dosage and duration of omega-3 PUFA intake...
August 28, 2018: Cardiovascular Diabetology
James B Young, Marjolaine Gauthier-Loiselle, Robert A Bailey, Ameur M Manceur, Patrick Lefebvre, Morris Greenberg, Marie-Hélène Lafeuille, Mei Sheng Duh, Brahim Bookhart, Carol H Wysham
BACKGROUND: There exist several predictive risk models for cardiovascular disease (CVD), including some developed specifically for patients with type 2 diabetes mellitus (T2DM). However, the models developed for a diabetic population are based on information derived from medical records or laboratory results, which are not typically available to entities like payers or quality of care organizations. The objective of this study is to develop and validate models predicting the risk of cardiovascular events in patients with T2DM based on medical insurance claims data...
August 24, 2018: Cardiovascular Diabetology
Naim Shehadeh, Itamar Raz, Afif Nakhleh
No abstract text is available yet for this article.
August 22, 2018: Cardiovascular Diabetology
Hironori Takahashi, Noriaki Iwahashi, Jin Kirigaya, Shunsuke Kataoka, Yugo Minamimoto, Masaomi Gohbara, Takeru Abe, Kozo Okada, Yasushi Matsuzawa, Masaaki Konishi, Nobuhiko Maejima, Kiyoshi Hibi, Masami Kosuge, Toshiaki Ebina, Kouichi Tamura, Kazuo Kimura
BACKGROUND: Impaired glucose metabolism is an established risk factor for coronary artery disease. Previous studies revealed that glycemic variability (GV) is also important for glucose metabolism in patients with acute coronary syndrome (ACS). We explored the association between GV and prognosis in patients with ACS. METHODS: A total of 417 patients with ACS who received reperfusion wore a continuous glucose monitoring system (CGMS) in a stable phase after admission and were monitored for at least 24 consecutive h...
August 18, 2018: Cardiovascular Diabetology
Maayan Waldman, Keren Cohen, Dor Yadin, Vadim Nudelman, Dan Gorfil, Michal Laniado-Schwartzman, Ran Kornwoski, Dan Aravot, Nader G Abraham, Michael Arad, Edith Hochhauser
Unfortunately, after publication of this article [1], it was noticed that Table 1 contained errors introduced during the production process. In the WT + AT column, the FS value is 21 ± 7 and the Body Weight value is 25 ± 2. In the WT + AT + CR column, the FS value is 46 ± 14 and the Body Weight value is 19 ± 1. The original article has been updated to reflect this.
August 17, 2018: Cardiovascular Diabetology
Peter Blomstrand, Peter Sjöblom, Mats Nilsson, Magnus Wijkman, Martin Engvall, Toste Länne, Fredrik H Nyström, Carl Johan Östgren, Jan Engvall
AIMS: Obesity is associated with type 2 diabetes mellitus, left ventricular diastolic dysfunction and heart failure but it is unclear to which extent it is related to left ventricular systolic dysfunction. The aim of the study was to explore the effects of overweight and obesity on left ventricular systolic function in patients with type 2 diabetes mellitus and a control group of non-diabetic persons. METHODS: We prospectively investigated 384 patients with type 2 diabetes mellitus, and 184 controls who participated in the CARDIPP and CAREFUL studies...
August 14, 2018: Cardiovascular Diabetology
Xiao-Fang Tang, Yuan-Liang Ma, Ying Song, Jing-Jing Xu, Yi Yao, Chen He, Huan-Huan Wang, Ping Jiang, Lin Jiang, Ru Liu, Zhan Gao, Xue-Yan Zhao, Shu-Bin Qiao, Yue-Jin Yang, Run-Lin Gao, Bo Xu, Jin-Qing Yuan
BACKGROUND: To improve outcomes in patients with diabetes mellitus (DM) undergoing percutaneous coronary intervention remain an unmet clinical need. The study aimed to evaluate the efficacy and safety of G2-DESs and BP-DESs in patients with and without DM in a single center in China. METHODS: A total of 7666 consecutive patients who exclusively had G2-DES or BP-DES implantation throughout 2013 in our center were studied. The primary efficacy endpoint was any target lesion revascularization (TLR), whereas the primary safety endpoint was a composite of death or myocardial infarction (MI) at 2-year follow-up...
August 14, 2018: Cardiovascular Diabetology
Jun Murai, Hitoshi Nishizawa, Akihito Otsuka, Shiro Fukuda, Yoshimitsu Tanaka, Hirofumi Nagao, Yasuna Sakai, Masahide Suzuki, Shinji Yokota, Hidetoshi Tada, Mayumi Doi, Yuya Fujishima, Shunbun Kita, Tohru Funahashi, Norikazu Maeda, Tadashi Nakamura, Iichiro Shimomura
BACKGROUND: Although obesity-related type 2 diabetes mellitus (T2DM) and sarcopenia in the elderly have been increasing worldwide, the associations among visceral fat accumulation, skeletal muscle indices (mass, strength, and quality) and cardiovascular diseases in T2DM remain poorly investigated. METHODS: We enrolled 183 Japanese T2DM inpatients (126 men, 57 women; mean age 64.7 ± 12.6 years, ± SD). The estimated-visceral fat area (eVFA) and skeletal muscle mass were measured by each device using bioelectrical impedance analysis method...
August 4, 2018: Cardiovascular Diabetology
Gilberto Velho, Stéphanie Ragot, Ray El Boustany, Pierre-Jean Saulnier, Mathilde Fraty, Kamel Mohammedi, Frédéric Fumeron, Louis Potier, Michel Marre, Samy Hadjadj, Ronan Roussel
BACKGROUND: Cardiovascular disease and kidney damage are tightly associated in people with type 2 diabetes. Experimental evidence supports a causal role for vasopressin (or antidiuretic hormone) in the development of diabetic kidney disease (DKD). Plasma copeptin, the COOH-terminal portion of pre-provasopressin and a surrogate marker of vasopressin, was shown to be positively associated with the development and progression of DKD. Here we assessed the association of plasma copeptin with the risk of cardiovascular events during follow-up in two prospective cohorts of type 2 diabetic patients, and we examined if this association could be mediated by deleterious effects of vasopressin on the kidney...
August 2, 2018: Cardiovascular Diabetology
Jae-Seung Yun, Yong-Moon Park, Seon-Ah Cha, Yu-Bae Ahn, Seung-Hyun Ko
BACKGROUND: To examine whether the progression rate of cardiovascular autonomic neuropathy (CAN) stage is an independent predictive factor for cardiovascular disease (CVD) in type 2 diabetes. METHODS: Standardized cardiovascular autonomic reflex tests (CARTs) using traditional Ewing method were performed at baseline. The follow-up CARTs was recommended once every two years. We estimated the primary CVD endpoint, defined as coronary artery disease and ischemic stroke...
August 2, 2018: Cardiovascular Diabetology
Maayan Waldman, Keren Cohen, Dor Yadin, Vadim Nudelman, Dan Gorfil, Michal Laniado-Schwartzman, Ran Kornwoski, Dan Aravot, Nader G Abraham, Michael Arad, Edith Hochhauser
BACKGROUND: Metabolic disorders such as obesity, insulin resistance and type 2 diabetes mellitus (DM2) are all linked to diabetic cardiomyopathy that lead to heart failure. Cardiomyopathy is initially characterized by cardiomyocyte hypertrophy, followed by mitochondrial dysfunction and fibrosis, both of which are aggravated by angiotensin. Caloric restriction (CR) is cardioprotective in animal models of heart disease through its catabolic activity and activation of the expression of adaptive genes...
August 2, 2018: Cardiovascular Diabetology
Annayya R Aroor, Nitin A Das, Andrea J Carpenter, Javad Habibi, Guanghong Jia, Francisco I Ramirez-Perez, Luis Martinez-Lemus, Camila M Manrique-Acevedo, Melvin R Hayden, Cornel Duta, Ravi Nistala, Eric Mayoux, Jaume Padilla, Bysani Chandrasekar, Vincent G DeMarco
BACKGROUND: Arterial stiffness is emerging as an independent risk factor for the development of chronic kidney disease. The sodium glucose co-transporter 2 (SGLT2) inhibitors, which lower serum glucose by inhibiting SGLT2-mediated glucose reabsorption in renal proximal tubules, have shown promise in reducing arterial stiffness and the risk of cardiovascular and kidney disease in individuals with type 2 diabetes mellitus. Since hyperglycemia contributes to arterial stiffness, we hypothesized that the SGLT2 inhibitor empagliflozin (EMPA) would improve endothelial function, reduce aortic stiffness, and attenuate kidney disease by lowering hyperglycemia in type 2 diabetic female mice (db/db)...
July 30, 2018: Cardiovascular Diabetology
Zoltán Kiss, György Rokszin, Zsolt Abonyi-Tóth, György Jermendy, Péter Kempler, Dániel Aradi, István Wittmann
BACKGROUND: The excess risks of mortality and cardiovascular morbidity among patients with type 2 diabetes mellitus (T2DM) is well known. In this nationwide study, we assessed risks of mortality and cardiovascular events comparing patients with T2DM and matched controls. METHODS: We identified patients with T2DM in a retrospective cohort study using the database of the National Health Insurance Fund between 1 January 2010 and 31 December, 2013. Controls were randomly included and matched according to age, gender, and zip code of residence...
July 27, 2018: Cardiovascular Diabetology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"